摘要
目的:探讨加贝酯联合生长抑素治疗胰腺炎近期疗效及对炎症因子、D-乳酸的影响。方法:选择2017年1月至2010年1月在我院接受治疗的急性胰腺炎患者80例为研究对象,按照随机数表法分为对照组(n=40)和试验组(n=40)。对照组采用生长抑素治疗,实验组采用加贝酯联合生长抑素治疗,比较两组临床疗效、腹部体征与胃肠道功能恢复时间、血清CRP、TNF-α、IL-6、D-乳酸水平及血淀粉酶、尿淀粉酶、脂肪酶水平。并统计两组不良反应发生情况。结果:试验组组总有效率为75.00%(30/40),试验组总有效率为92.50%(37/40),两组比较有统计学意义(P<0.05)。试验组腹部体征消失时间及胃肠道功能恢复时间均明显短于对照组,差异有统计学意义(P<0.05)。治疗前,两组CRP、TNF-α、IL-6、D-乳酸水平及血淀粉酶、尿淀粉酶、脂肪酶水平比较无统计学差异(P>0.05);治疗后,试验组血清CRP、TNF-α、IL-6、D-乳酸水平及血淀粉酶、尿淀粉酶、脂肪酶水平均明显低于对照组(P<0.05)。两组患者均发生不同程度的多器官功能衰竭、假性囊肿已经胰周感染,其试验组发生率为7.5%(3/40),对照组发生率为17.5%(7/40),两组比较具有统计学意义(P<0.05)。结论:加贝酯联合生长抑素治疗胰腺炎可有效改善患者炎症因子水平及肠粘膜功能,更利于快速控制病情,从而显著提高临床疗效。
Objective: To investigate the short-term efficacy of Gabexate combined with somatostatin in the treatment of pancreatitis and its effect on inflammatory factors and d-lactic acid. Methods: 80 patients with acute pancreatitis who were treated in our hospital from January 2017 to January 2010 were selected as the study subjects and randomly divided into the control group(n=40) and the experimental group(n=40). The control group was treated with somatostatin, and the experimental group was treated with Gabexate combined with somatostatin. The clinical efficacy, abdominal signs and recovery time of gastrointestinal function, serum CRP, TNF-α,IL-6, d-lactic acid levels, blood amylase, urinary amylase and lipase levels of the two groups were compared. And statistics of the two groups of adverse reactions. Results: The total effective rate was 75.00%(30/40) in the control group and 92.50%(37/40) in the experimental group. The comparison between the two groups was statistically significant(P<0.05). The disappearance time of abdominal signs and recovery time of gastrointestinal function in the experimental group were significantly shorter than those in the control group,with statistically significant differences(P<0.05). Before treatment, there was no statistical difference in the levels of CRP, TNF-α, IL-6,d-lactic acid, blood amylase, urinary amylase and lipase between the two groups(P>0.05). After treatment, serum levels of CRP, TNF-α,IL-6, d-lactic acid, blood amylase, urinary amylase and lipase in the test group were significantly lower than those in the control group(P<0.05). Two groups of patients are different degree of multiple organ failure, pseudocyst had peripancreatic infection, the incidence of the experimental group was 7.5%(3/40), the incidence of the control group was 17.5%(7/40), comparing the two groups have statistical significance(P<0.05). Conclusion: Gabexater combined with somatostatin in the treatment of pancreatitis can effectively improve the level of inflammatory factors and intestinal mucosal function of patients, more conducive to the rapid control of the disease, thus significantly improving the clinical efficacy.
作者
毛庆
李海山
蔡兆辉
左爽
张琪
MAO Qing;LI Hai-shan;CAI Zhao-hui;ZUO Shuang;ZHANG Qi(Department of Emergency,Hefei Second People's Hospital,Hefei,Anhui,230011,China)
出处
《现代生物医学进展》
CAS
2020年第15期2991-2995,共5页
Progress in Modern Biomedicine
基金
安徽省科技攻关计划项目(1301042206)。
关键词
加贝酯
生长抑素
急性胰腺炎
近期疗效
D-乳酸
Gabexater
Somatostatin
Acute pancreatitis
Short-term efficacy
D-lactic acid
